Advertisements
Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category


#NYVS19#NewYorkVentureSummit July 9th – 10th, Where #innovation Meets #Capital#startups connect with over 150 #AwesomeVCs& #Angels.http://bit.ly/30E9ci5 $100 off with Discount Code:LPBIVIP

 

From: “Gil Garalnick [FinTrack Venture Summit]” <Gil@youngstartup.com>

Date: Sunday, June 23, 2019 at 11:19 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, Preston Michaels <preston@youngstartup.com>, Jukka K <jukan_koti@hotmail.com>

Subject: RE: youngStartup Ventures

Hi Aviva–

Pleased to share an updated list of over 120 VCs and Angels already confirmed to speak and judge at the New York Venture Summit (below).

Would it be feasible to share an email update before the end of June? I can send updated copy.

Attached updated social media copy below. Feel free to share with your network. Your network is now entitled to an additional $100 off the current rates ($400 off the on the door rate) using the same discount code (LPBIVIP). They should register as soon as possible to lock in the lowest possible rates.

Twitter

 

#NYVS19#NewYorkVentureSummit July 9th – 10th, Where #innovation Meets #Capital#startups connect with over 150 #AwesomeVCs& #Angels.http://bit.ly/30E9ci5 $100 off with Discount Code:LPBIVIP

 

Where do #startups connect with over 150 #AwesomeVCs& #Angels? #NYVS19#NewYorkVentureSummit July 9-10, Where #innovation Meets #CapitalExtra 10% off early bird rates.http://bit.ly/30E9ci5 $100 off with Discount Code:LPBIVIP

 

Facebook

Leaders in Pharmaceutical Business Intelligence Group invites you to attend #NYVS19#NewYorkVentureSummitJuly 9th – 10th, Where #innovation Meets #Capital#startups connect with over 150 #AwesomeVCs& #Angels. $100 off with Discount Code:LPBIVIP

 

LinkedIn

Leaders in Pharmaceutical Business Intelligence Group invites you to attend #NYVS19#NewYorkVentureSummitJuly 9th – 10th, Where #innovation Meets #Capital#startups connect with over 150 #AwesomeVCs& #Angels. $100 off with Discount Code:LPBIVIP

 

Whether you are an investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, #NYVS19is one event you won’t want to miss.

 

Partial list of over 120 VCs and Angels confirmed to speak and judge includes:

Jenny Abramson, Founder & Managing Partner, Rethink Impact | Nick Adams, Managing Partner & Co-Founder, Differential Ventures | Karine Agajanian, Senior Analyst, Anzu Partners | John Albright, Managing Partner, Relay Ventures | Andrew Aldrich, Principal, American Family Ventures | Jay Amarasekera, Senior Technology Manager, SABIC Ventures | Mark Austin, Managing Director, Viridian Capital | Michael Baldwin, Senior Associate, Moderne Ventures | Natalie Bartlett, Investor, General Catalyst | Liza Benson, Partner, Moderne Ventures | Lily Bernicker, Associate, Collaborative Fund | Eric Bielke, Investment Director, GE Ventures | Laura Bock, Investor, QED Investors | Eric Breese, Investment Manager, Evonik Venture Capital | Matt Brennan, Partner, General Catalyst Partners | Joel Brightfield, Principal, SixThirty | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Don Burton, Founding & Managing Partner, LearnStart | Jason Cahill, Founder & Managing Director, Carbon Ventures | Alex Carusillo, Venture Associate, OCA Ventures | Benjamin Cukier, Founder, Centana Growth Partners | Soraya Darabi, General Partner, Trail Mix Ventures | Tyler Dean, Investor, Point72 Ventures | Parth Desai, Investor, Flare Capital Partners | Alan Du, Investor, Millennium Technology Value Partners | Tyler Durham, Principal, Schlumberger Ventures | Kenny Estes, Co-Founder & Partner, West Loop Ventures | Dave Fan, Principal, Alumni Ventures Group | Michael Fanfant, Senior Associate, Runa Capital | Matt Fates, Founder & General Partner, Pulse Ventures | Sana Fathima, Investment Manager, Lockheed Martin Ventures | Mark G. Fields, Partner, Alsop Louie Partners | Linda Fingerle, President and Managing Director, Tappan Hill Ventures | Lindsay Fitzgerald, Managing Director, American Express Ventures | Haley Fradkin, Investment Associate, Plum Alley Investments | Daniel Franke, Associate, M Ventures | Ben Freeberg, Senior Associate, Alpha Venture Partners | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Alexander Galitsky, Co-Founder and Managing Partner, Almaz Capital | Anna Garcia, General Partner, Runway Venture Partners | Elaine Gilde, Board Member, New York Angels | Stephen Gilfus, Founder, Blackboard Inc. | Karim Gillani, General Partner, Luge Capital | Samara Gordon, Senior Associate, Hyperplane Venture Capital | Edward Greer, Corporate Technology Scout, Dow Ventures | Amanda Groves, Partner, PLUS Capital | John Gu, Investor, Spring Mountain Capital | Whitney Haring-Smith, Managing Partner, Anzu Partners | Will Hawkins, Senior Associate, Founder Collective | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Cat Hernandez, Partner, Primary Venture Partners | Ann Hickey, Vice President, Town Hall Ventures | Kyle Howard-Johnson, Investor, Catalyst Investors | Vinay Iyengar, Investor, Bessemer Venture Partners | Deborah Jackson, Founder, Plum Alley Investments | Dhruv Jain, Investor, Bessemer Venture Partners | Christina Jenkins, Lead Investor, Portfolia | Del Johnson, Principal, Backstage Capital | Jay Karandikar, Venture Partner, New Crop Capital | Hana Khosla, Investor, Activant Capital | Avery Klemmer, Investor, FirstMark Capital | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Steve Konsek, Program Director, National Science Foundation | George Krautzel, Managing Partner, MissionOG | Ricky Lai, Senior Associate, Portag3 Ventures | Eddie Lee, Senior Associate, White Star Capital | Oivind Lorentzen, Investor, Oak HC/FT | Marissa Lowman, Head of Education Practice, Village Capital | Bion Ludwig, Partner, Savano Capital Partners | Coppelia Marincovic, Investment Manager, Solvay Ventures | Elizabeth McCluskey, Principal, Impact Engine | Shripal Meghani, Partner, Cleveland Clinic Ventures | Arpesh Mehta, Investment Director, DSM Venturing | Andrée-Lise Méthot, Founder & Managing Partner, Cycle Capital Management | Ed Michael, Co-founder and Managing Partner, LionBird Ventures | Bá Minuzzi, General Partner, BABEL Ventures | Karolina Mrozkova, Associate, White Star Capital | Sonia Nagar, Partner, Pritzker Group Venture Capital | Greg Neufeld, Partner, ValueStream Ventures | Stuart O’Keeffe, Principal, Great Oaks Venture Capital | Jason Palmer, General Partner, New Markets Venture Partners | Victor Pascucci III, Managing Partner, Lightbank | Matt Perlman, Principal, IA Capital Group | Victoria Pettibone, Managing Director, Astia Angels | Daniel Pianko, Partner, University Ventures | Adam Plotkin, Partner, ff Venture Capital | Jean-Noel Poirier, Managing Partner, Clean Energy Venture Group | Greg Pope, Principal, Anzu Partners | Bryan Rabenau, Principal, BP Ventures | Suraj Kumar Rajwani, General Partner, DoubleRock | K.P. Reddy, Founder, Shadow Ventures | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital | Douglas Roth, Managing Director, Connecticut Innovations | Boris Ryabov, Managing Partner, Bright Capital | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Zak Schwarzman, Partner, MetaProp | Thomas Seo, Vice President, Citi Ventures | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Jaidev Shergill, Managing Partner, Capital One Growth Partners | Zacary Sherman, Associate, Pereg Ventures | Nicole Shimer, Investment Associate, Insight Partners | Bennett Siegel, Investor, Coatue Management | Raj Singh, Managing Partner, JetBlue Technology Ventures | Jean Sini, Angel Investor | Corinne Spears, Associate, University Ventures | Lutz Stoeber, Investment Director, Evonik Venture Capital | Neil Swami, Principal, Catalyst Health Ventures | Erica Van, Associate, Charles River Ventures | Maria Velissaris, Founding Partner, SteelSky Ventures | Patrick Walsh, Director, National Grid Partners | Jamie M. Weston, Managing Director, Spring Mountain Capital | Simon Wu, Principal, Cathay Innovation | Anthony Xu, Partner, New Ground Ventures | Lisa Xu, Investor, FirstMark Capital | Wesley Yiu, Senior Associate, Triphammer Ventures | Chris Young, Partner, Revel Partners | Greg Zaic, General Partner, NMT Capital | Katherine Zamsky, Managing Partner, Carbon Ventures | Stephanie Zepeda, Senior Associate, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chris Zock, Managing Director , Sandbox Insurtech Ventures and many more.

Regards

Gil

 

Gil Garalnick

Associate 

youngStartup Ventures

“Where Innovation Meets Capital”

 

p: 212.202.1002

e: gil@youngstartup.com

u: www.youngstartup.com

 

Advertisements

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

Each country have their own needs and most important drug cost structure. Must involve patients and providers.
BCI survey: countries output different, who improved who didnt
Is industry having collaboration with government? hardly ten percent by survey and worse vice versa
Transparancy and holistic view important for collaboration
Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments
Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance
Pitts: we need trust; staff that country offices with people who know that country. Price not defining value
Columbia:  need to attract investors

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

 

Results from Clarivate
In 2018 most of deals were in CART area but now we are seeing more series A rounds that are on novel mechanisms as well as rare diseases.  US is still highest in venture capital series A but next is China. 10 of top ex US VC are from China, a whole lot of money.
Preclinical is very strong for US VC but China VC is focused on clinical.  First time this year we see US series A break above 100.  But ex US the series A is going down.  Although preclinical deals in US is coming back not like as good as in 2006.  But alot of > 1 billion $ deals.  Most of money into mAbs and protein therapy;  antisense is big and cell therapy is big too; small molecule not as much
ClearView Healthcare
Which innovation classes attracted VC in 2018?
  • Oncology drives a disproportionate focus could be driven by pharma focus on oncology; however there is some focus on neuro and infectious disease
  • therapeutic classes: shift to differentiated technology…. companies want technologic platforms not just drugs.  Nucleic Acid tech and antibody tech is high need platforms.  Startups can win by developing a strong platform not just a drug
There are pros and cons of developing a platform company versus a focused company.  Many VCs have a portfolio and want something to fit in so look for a focused company and may not want a platform company.  Pfizer feels that when alot of money is available (like now) platform investing is fine but when money becomes limited they will focus on those are what will be needed to fill therapy gaps.  They believe buy the therapy and only rent the platform.
Merck does feel the way Pfizer does but they have separate ventures so they can look and license platforms.  they are active in looking at companies with new modalities but they are focused on the money so they feel best kept in hands of biotech not pharma.
At Celgene they were solely focused on approvals not platforms.  Alot of money is required to get these platforms to market.  Concentration for platform companies should be the VCs not partnering or getting bought out by pharma.  it seems from panel speakers from pharma that they are waiting for science to prove itself and waiting for favorable monetary environments (easy money).  However it seems they (big pharma) are indicating that money is drying up or at least expect it too.
At Axial and with VCs they feel it is important to paint a picture or a vision at the early stage.
At Ontogeny, they focus on evaluating assets especially and most important, ThE MANAGEMENT TEAM.  There are not that many great talented drug development management teams he feels out there even though great science out there.

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3, Philadelphia PA

Reporter: Stephen J. Williams PhD @StephenJWillia2

 

Larry Blandford PharmD from Precision Medicine Group gave introduction about development of precision oncology medicine.  Talked about value and value determination for partnerships.

Company Pitches:

Kernal Biologics: Preclinical immunotherapy company developing mRNA therapeutics.  Their therapy only have activity in p53 deficient cells (messenger 2.0).  They identified, by screening, multiple mRNAs that have oncoselectivity; ONC-333 is their lead mRNA active in AML and NSCLC.  Looking for 5.5M seed $

Vaccibody AS: Vaccine technology from Oslo University to target antigen to antigen presenting cells.  They are targeting the myocytes and dimerize the antigen to MHC.  Targeting melanoma, certain cervical cancers, and hemotologic cancers.  Technology based on identified neoantigens obtained from tumor biopsy.Three vaccines: VB10.neo  VB10.16 against HPV cervical

Chimeric Therapeutics: developing CART to solid malignancies against CLEC14 (tumor endothelial marker), may make tumor susceptible to hypoxia.  Targeting pancreatic cancer, prelim results in mice , efficacy of 15%, working on 3rd generation CART

Memo Therapeutics: Antibody therapeutics; based on Dropzylla single B cell sorting and subsequent screening for mAb.  Targeting checkpoint inhibitors on solid tumors;  have a new target other than PD1; target undisclosed on NK cells and T cells; Early stage have academic partners; seeking 20Million Swiss Francs

Takeda Oncology: Chris Hurff Senior Director Business Development; they depend on partnerships as they feel internal RD is less effective.  They are diversifying their portfolio from small molecules. They have over 200 partnerships (132 in Boston). They are focusing on heme, lung, and Immunooncology. Partnering model: CEI (center external innovation) deals with both academic and small biotechs.  They have numerous partners including Shatto and MD Anderson.

 

 

Read Full Post »


Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Please check daily on this OPEN ACCESS JOURNAL for updates on one of the most important BIO Conferences of the year for meeting notes, posts, as well as occasional PODCASTS.

 

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.  The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

 

Keynote Speakers INCLUDE:

Fireside Chat with Margaret (Peggy) Hamburg, MD, Foreign Secretary, National Academy of Medicine; Chairman of the Board, American Association for the Advancement of Science

Tuesday Keynote: Siddhartha Mukherjee (Author of the bestsellers Emperor of All Maladies: A Biography of Cancer and  The Gene: An Intimate History)

Fireside Chat with Jeffrey Solomon, Chief Executive Officer, COWEN

Fireside Chat with Christi Shaw, Senior Vice President and President, Lilly BIO-Medicines, Eli Lilly and Company

Wednesday Keynote: Jamie Dimon (Chairman JP Morgan Chase)

Fireside Chat with Kenneth C. Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

Fireside Chat: Understanding the Voices of Patients: Unique Perspectives on Healthcare

Fireside Chat: FDA Town Hall

 

ALSO SUPERSESSIONS including:

Super Session: What’s Next: The Landscape of Innovation in 2019 and Beyond

Super Session: Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Digital Health in Practice: A Conversation with Ameet Nathawani, Chief Digital Officer, Chief Medical Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Realizing the Promise of Gene Therapies for Patients Around the World

Super Session: Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Super Session: The Art & Science of R&D Innovation and Productivity

Super Session: Dealmaker’s Intentions: 2019 Market Outlook

Super Session: The State of the Vaccine Industry: Stimulating Sustainable Growth

 

See here for full AGENDA

Link for Registration: https://convention.bio.org/register/

The BIO International Convention is literally where hundreds of deals and partnerships have been made over the years.

 

BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

In addition, we produce BIOtechNOW, an online blog chronicling ‘innovations transforming our world’ and the BIO Newsletter, the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

 

Membership with the Biotechnology Innovation Organization (BIO)

BIO has a diverse membership that is comprised of  companies from all facets of biotechnology. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies – 90 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. Learn more about how you can save with BIO Membership.

BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • 66% R&D-Intensive Companies *Of those: 89% have annual revenues under $25 million,  4% have annual revenues between $25 million and $1 billion, 7% have annual revenues over $1 billion.
  • 16% Nonprofit/Academic
  • 11% Service Providers
  • 7% State/International Affiliate Organizations

Other posts on LIVE CONFERENCE COVERAGE using Social Media on this OPEN ACCESS JOURNAL and OTHER Conferences Covered please see the following link at https://pharmaceuticalintelligence.com/press-coverage/

 

Notable Conferences Covered THIS YEAR INCLUDE: (see full list from 2013 at this link)

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT

https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg

http://kochinstituteevents.cvent.com/events/koch-institute-2019-immune-engineering-symposium/event-summary-8d2098bb601a4654991060d59e92d7fe.aspx?dvce=1

 

  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

 

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda-list/

https://worldmedicalinnovation.org/

 

  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

http://www.giiconference.com/chi653337/

https://pharmaceuticalintelligence.com/2019/04/22/18th-annual-2019-bioit-conference-expo-april-16-18-2019-boston-seaport-world-trade-center-track-5-next-gen-sequencing-informatics-advances-in-large-scale-computing/

 

  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

https://pharmaceuticalintelligence.com/2019/04/25/translating-genetics-into-medicine-april-25-2019-830-am-600-pm-the-new-york-academy-of-sciences-7-world-trade-center-250-greenwich-st-fl-40-new-york/

 

  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge

https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/

 

  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

https://pharmaceuticalintelligence.com/2019/01/11/2019-petrie-flom-center-annual-conference-consuming-genetics-ethical-and-legal-considerations-of-new-technologies/

 

  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

https://pharmaceuticalintelligence.com/2019/03/12/2019-koch-institute-symposium-machine-learning-and-cancer-june-14-2019-800-am-500-pmet-mit-kresge-auditorium-48-massachusetts-ave-cambridge-ma/

 

Read Full Post »


Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to announce its sponsorship and invite you to attend the Dedicated Lifesciences/Healthcare Track at New York Venture Summit presented by youngStartup Ventures.

 

 

 

Official Logo of Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

 

Special discount.  Use discount code LPBIVIP and receive 10% off the “early bird” rates. Early bird rates expire at the end of May.

 

>> Call for Top Lifesciences/Healthcare Innovators to present to leading Investors (details below).

 

New York

Venture Summit

July 9th & 10th 2019 | Convene | New York City

 

Where Innovation Meets Capital

 

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Dedicated Lifesciences/Healthcare Track at the prestigious New York Venture Summit being held on July 9th & 10th 2019 at Convene, New York City.

 

Whether you’re a Lifesciences/Healthcare  startup seeking capital and exposure, or an investor seeking new deals, The New York Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, The New York Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage Lifesciences/Healthcare companies.

 

Partial list of VCs and Angels confirmed to speak and judge includes:

Jenny Abramson, Founder & Managing Partner, Rethink Impact | Nick Adams, Managing Partner & Co-Founder, Differential Ventures | Karine Agajanian, Senior Analyst, Anzu Partners | John Albright, Managing Partner, Relay Ventures | Andrew Aldrich, Principal, American Family Ventures | Liza Benson, Partner, Moderne Ventures | Lily Bernicker, Associate, Collaborative Fund | Laura Bock, Investor, QED Investors | Matt Brennan, Partner, General Catalyst Partners | Joel Brightfield, Principal, SixThirty | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Don Burton, Founding & Managing Partner, LearnStart | Jason Cahill, Founder & Managing Director, McCune Capital | Alex Carusillo, Venture Associate, OCA Ventures | Benjamin Cukier, Founder, Centana Growth Partners | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Soraya Darabi, General Partner, Trail Mix Ventures | Tyler Dean, Investor, Point72 Ventures | Parth Desai, Investor, Flare Capital Partners | Alan Du, Investor, Millennium Technology Value Partners | Tyler Durham, Principal, Schlumberger Ventures | Miriam Eaves, Venture Partner, BP Ventures | Kenny Estes, Co-Founder & Partner, West Loop Ventures | Dave Fan, Principal, Alumni Ventures Group | Michael Fanfant, Senior Associate, Runa Capital | Matt Fates, Founder & General Partner, Pulse Ventures | Sana Fathima, Investment Manager, Lockheed Martin Ventures | Lindsay Fitzgerald, Managing Director, American Express Ventures | Haley Fradkin, Investment Associate, Plum Alley Investments | Ben Freeberg, Senior Associate, Alpha Venture Partners | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Anna Garcia, General Partner, Runway Venture Partners | Stephen Gilfus, Founder, Blackboard Inc. | Karim Gillani, General Partner, Luge Capital | Edward Greer, Corporate Technology Scout, Dow Ventures | John Gu, Investor, Spring Mountain Capital | Whitney Haring-Smith, Managing Partner, Anzu Partners | Will Hawkins, Senior Associate, Founder Collective | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Ann Hickey, Vice President, Town Hall Ventures | Kyle Howard-Johnson, Investor, Catalyst Investors | Vinay Iyengar, Investor, Bessemer Venture Partners | Deborah Jackson, Founder, Plum Alley Investments | Dhruv Jain, Investor, Bessemer Venture Partners | Del Johnson, Principal, Backstage Capital | Jay Karandikar, Venture Partner, New Crop Capital | Hana Khosla, Investor, Activant Capital | Avery Klemmer, Investor, FirstMark Capital | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Steve Konsek, Program Director, National Science Foundation | George Krautzel, Managing Partner, MissionOG | Ricky Lai, Senior Associate, Portag3 Ventures | Eddie Lee, Senior Associate, White Star Capital | Bion Ludwig, Partner, Savano Capital Partners | Coppelia Marincovic, Investment Manager, Solvay Ventures | Elizabeth McCluskey, Principal, Impact Engine | Shripal Meghani, Partner, Cleveland Clinic Ventures | Arpesh Mehta, Investment Director, DSM Venturing | Andrée-Lise Méthot, Founder & Managing Partner, Cycle Capital Management | Ed Michael, Co-founder and Managing Partner, LionBird Ventures | Sarah Millar, Associate, City Light Capital | Bá Minuzzi, General Partner, BABEL Ventures | Greg Neufeld, Partner, ValueStream Ventures | Jason Palmer, General Partner, New Markets Venture Partners | Matt Perlman, Principal, IA Capital Group | Victoria Pettibone, Managing Director, Astia Angels | Daniel Pianko, Partner, University Ventures | Adam Plotkin, Partner, ff Venture Capital | Jean-Noel Poirier, Managing Partner, Clean Energy Venture Group | Greg Pope, Principal, Anzu Partners | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital | Douglas Roth, Managing Director, Connecticut Innovations | Boris Ryabov, Managing Partner, Bright Capital | Ernst Sack, Partner, Blue Bear Capital | Zak Schwarzman, Partner, MetaProp | Thomas Seo, Vice President, Citi Ventures | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Jaidev Shergill, Managing Partner, Capital One Growth Partners | Zacary Sherman, Associate, Pereg Ventures | Nicole Shimer, Investment Associate, Insight Venture Partners | Raj Singh, Managing Partner, JetBlue Technology Ventures | Jean Sini, Angel Investor | Neil Swami, Principal, Catalyst Health Ventures | Erica Van, Associate, Charles River Ventures | Jamie M. Weston, Managing Director, Spring Mountain Capital | Anthony Xu, Partner, New Ground Ventures | Lisa Xu, Investor, FirstMark Capital | Wesley Yiu, Senior Associate, Triphammer Ventures | Chris Young, Partner, Revel Partners | Katherine Zamsky, Managing Partner, Carbon Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Greg Ziac, General Partner, NMT Capital | Chris Zock, Managing Director , Sandbox Insurtech Ventures and many more.

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence Group has made special arrangement for our network to receive a special discount, currently 10% off the existing “early bird” savings. Early bird rates expire at the end of May.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   

(Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators from the Technology, Life Sciences/Healthcare, CleanTech and Fintech sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

&

youngStartup Ventures

Read Full Post »


MIXiii-BIOMED 2019 – The 18th National Life Science & Technology Week, May 14-16, 2019, David InterContinental, Tel Aviv, Israel

 

 

Daily Program

NB: Please check program on site in case of last minute changes.

Time slots in blue text indicate Company Presentations. Click on company name to view abstract.

14 May 2019

+
09:30  –  11:20
Hall A

Opening Session

09:30-10:00 Welcome by Conference Chairpersons:
Ruti Alon, Founder and CEO, Medstrada
Ora Dar, PhD, Israel Innovation Authority
Nissim Darvish, MD, PhD, Senior Managing Director, Orbimed Advisors

10:00-10:40 Robert C. King, PhD, Partner at Goldman Sachs International and Global Vice Chairman, Investment Banking Division: “Current Developments in Healthcare Capital Markets and M&A”

10:40-11:20 Barry Greene, President, Alnylam Pharmaceuticals: “Nobel Prize-Winning Science to First Approved RNAi therapeutic”

+
11:20  –  11:50

Coffee Break

+
11:50  –  17:40
Hall A

Gene Editing and Gene Therapy: The Next Frontier in Human Health

Co-chairs: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; Stephen Squinto, PhD, Interim CEO, Passage Bio

11:50-11:55 Opening by Co-chairs

11:55-12:20 Adi Barzel, PhD, Senior Lecturer, Department of Biochemistry at Tel Aviv University; Co-Founder of LogicBio Therapeutics, Inc.; President of the Israeli Society of Gene and Cell Therapy: “Principles of Gene Editing; CRISPR in B Cells Fighting AIDS”

12:20-12:40 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Novel Approaches for Antibody-targeted Intracellular Delivery of Large Nucleic Acids incl. CRISPR Mediated Gene Editing Modules”

12:40-13:00 Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco: “CRISPRa Therapeutics for Haploinsufficient Disease”

13:00-13:20 Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences

13:20-13:35 Kyle Chiang, PhD, VP Product Strategy, LogicBio Therapeutics“In Vivo Genome-editing for Rare Pediatric Diseases”

13:35-13:50 David Baram, PhD, Chief Executive Officer, Emendo Bio Inc“Emendo Biotherapeutics – High Precision Gene Editing with Next Generation CRISPR Nucleases”

13:50-15:20 Lunch Break

15:20-15:45 Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College: “Gene Therapy for CNS Disorders”

15:45-16:05 Stephen Squinto, PhD, Interim CEO, Passage Bio: “Passage Bio: Developing Transformative Genetic Medicines for Rare Monogenic CNS Diseases”

16:05-16:25 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; “Using Gene Therapy for the Treatment of Rare Genetic Liver Disease”

16:25-16:40 Trevor Martin, PhD, CEO and Co-Founder, Mammoth Biosciences: “The Next Generation of CRISPR Tools”

16:40-16:55 Dalia El-Ani, PhD, Chief Executive Officer, CRISPR Stem & Therapeutics“CRISPR: A Novel Gene Therapy to Protect the Heart from Acute Ischemic Damage”

16:55-17:40 “Panel Discussion
Panelists:
Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College
Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences
Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco
Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
Stephen Squinto, PhD, Interim CEO, Passage Bio

+
11:50  –  17:25
Hall B

Transforming Medicine: Artificial Intelligence and Digital Health

Co-chairs: Anat Naschitz, Managing Director, OrbiMed Advisors; Allen Kamer, Managing Partner, OurCrowd Qure

11:50-11:55 Opening by Co-chairs

11:55-12:20 Don Mathis, General Manager, Growth, Comcast NBCUniversal: “Changing Healthcare at Scale: How AI is Enabling Transformation”

12:20-12:45 Elliot Menschik, MD, PhD, Global Head Healthcare and Lifescience Startups, Amazon: “Democratizing AI/ML Capabilities and Accelerating their Impact on Healthcare”

12:45-13:00 Leif E. Pedersen, CEO, Dassault Systemes BIOVIA: “Real Life Examples of BioPharma Leveraging AI and Machine Learning”

13:00-13:15 Doron Behar, MD, PhD, CEO, Igentify“An End-to-end & Scalable Digital Platform Designed for Web-assisted Genetic Counselling”

13:15-13:30 Yaron Gurovich, CTO, FDNA“Hype vs. Hope: Using AI to Detect Disease”

13:30-13:45 Itay Bengad, CEO, MDGO: “Your Car Knows your Injuries”

13:50-15:20 Lunch Break

15:20-15:40 Avinatan Hassidim, Head of TLV Research, Google: “How Google uses Machine Learning for Medical Research”

15:40-15:55 Ziv Ofek, Founder and CEO, MDClone: “Democratizing Healthcare Data – today and Tomorrow”

15:55-16:10 Hadas Bitran, Head of Healthcare Israel, Microsoft: “Microsoft – Healthcare Innovation”

16:10-16:25 Tamara Mansfeld, Global Innovation Lead, Pfizer: “AI in Drug Discovery”

16:25-16:40 David Harel, Founder and CEO, CytoReason“Machine Learning for Drug Discovery and Development”

16:40-16:55 Avi Veidman, Founder and CEO, Nucleai“Harnessing AI for Pathology”

16:55-17:10 Ariel Beery, Founder and CEO, MobileODT“Using Augmented Reality at the Point of Care to Eliminate Cervical Cancer”

17:10-17:25 Micah Pearlman, COO, Biolojic Design“Making the Intractable Tractable: Designing Multi-Functional, Epitope Specific Antibodies using Machine Learning”

+
11:50  –  17:25
Hall C

Disruptive and Advanced Medical Devices

Co-chairs: Irit Yaniv, MD, General Partner, Accelmed; Ron Ginor, MD, Venture Partner, OrbiMed Advisors, L.L.C

11:50-11:55 Opening by Co-chairs

11:55-12:10 Bruce R. Rosengard, MD, VP, Global External Innovation, Johnson and Johnson Medical Devices: “Market Perspective”

12:10-12:25 Oren GoldshteinVectorius Medical Technologies“Transforming Heart Failure Treatment with the World’s First In-heart Microcomputer”

12:25-12:40 Ofri Vaisman, COO, Bluewind Medical“Bluewind Medical Renova System – Neurostimulation Therapy for Over Active Bladder”

12:40-12:55 Ron Aginsky, President, FUSMobile“Non-Invasive Procedure for Interventional Pain Managment Treatment”

13:00-13:15 Nicholas Pachuda, WW Vice President, Orthopedic Innovation, J&J Medical Devices: “Field Specific – Orthopedics”

13:15-13:30 Yehiel Tal, CEO, Collplant Ltd“rhCollagen – the Ideal Building Block for Regenerative Medicine”

13:30-13:45 Boaz Behar, CEO, Digma Medical“Restoring Glycemic Control in Patients with T2D”

13:50-15:20 Lunch Break

15:20-15:35 John J. Smith, MD, Partner, Hogan Lovells: “Regulatory Perspective”

15:35-15:50 Nitai Hanani, CEO, Paragate Medical“Implantable Peritoneal Ultrafiltration Device for Fluid Overload Treatment”

15:50-16:05 David Israeli, CEO, Magenta Medical“Minimally-Invasive Blood Pumps for the Treatment of Acute Heart Failure”

16:05-16:20 Prof. Joel V. Brill, MD, FACP, Chief Medical Officer, Predictive Health. LLC: “Reimbursement Perspective”

16:20-16:35 Yoram Solberg, MD, PhD, VP Clinical Affairs, Brainsgate“Spheno Palatine Ganglion Stimulation for Treatment of Acute Ischemic Stroke”

16:35-16:50 Nathalie Gilat, Senior Director, Nyxoah“Nyxoah – Sleep Apnea Healthtech Company”

16:50-17:05 Shai Policker, Medex Exlerator, “Incubator Perspective”

17:05-17:20 Eric Tansky, Managing Director, Oppenheimer & Co. Inc.: “Funding Perspective”

17:20-17:25 Closing by Co-chairs

15 May 2019

+
09:30  –  11:40
Hall A

Plenary Session

09:30-09:50 Amy W. Schulman, Managing Partner, LS Polaris Innovation Fund and Polaris Partners: “Building Early Stage Companies within the Biotech Ecosystem: Challenges and Opportunities”

09:50-10:10 Aharon Aharon, CEO, Israel Innovation Authority: “Bio-convergence – the Future of Israeli Healthtech”

10:10-11:00 Corporate Panel: Innovative Biotech/Large Companies/Capital: What’s the Right Formula to Bring Products to Patients?
Moderator: Francois Maisonrouge, Senior Managing Director, Evercore Partners
Panelists:
Fiona de Hemptinne, Venture Partner, UCB Ventures
Miriam Frieden, PhD, MBA, VP of Search and Evaluation, Novo Nordisk
Laurent Choppe, DVM, Managing Partner, Cukierman & Co. Life Sciences
Zafrira Avnur, PhD, CSO & Partner, VP Quark Venture Inc.
Tina Xu, Vice President of Information Technology and Head of Business Innovation, AstraZeneca China

11:00-11:40 Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer, Edwards Lifesciences:“Investing in Innovation”

 

+
11:40  –  12:10

Coffee Break

+
12:10  –  17:25
Hall A

Prevention and Rehabilitation: Should the Underdog Begin Barking?

Chair: Naomi Gefen, Deputy Director General, ALYN Hospital

Opening Session

12:10-12:25 Maurit Beeri, MD, Director General, ALYN Hospital: “From Prevention to Rehabilitation”

12:25-12:45 Yoav Medan, PhD: “The Technology Augmented Homo Sapiens“

Circle of Life: Prevention and Rehab for all ages

12:45-13:05 Sagit Arbel-Alon, MD, Deputy Director, Reuth Medical & Rehabilitation Hospital: “Geriatric Rehabilitation”

13:05-13:20 Rafi Fischer, Director of Media Communications, OrCam Technologies“OrCam Technologies – AI-Driven Artificial Vision”

13:20-13:35 Or Retzkin, CEO & Co-founder; EyeControl“EyeControl: Inspiring Communication”

13:35-13:55 Itamar Offer, MD, MPA, CEO, Sabar Health: “Rehabilitation at Home”

13:55-14:10 Yotam Drechsler, CEO, BrainQ technologies“BCI Based Stimulation Device- BQ (BrainQ technologies)”

14:10-15:40 Lunch Break

15:40-15:55 Maurit Beeri, MD, Director General, ALYN Hospital: “Pediatric Rehabilitation”

15:55-16:10 Yotam Bahat, CEO, SENSERUM“SENSERUM – VR for Clinical Use”

Taking Rehab to Another Level – Enabling Meaningful Participation in the Community and Workplace

16:10-16:25 Daniel Barel, CEO, SoftWheel“SoftWheel – Innovative Technology for Mobility Solutions”

16:25-16:50 Yaron Galitzky, General Manager, Devices & Accessories, Microsoft“Xbox Adaptive Controller”

16:50-17:15 Ziv Shilon, Co-founder, COO, 6Degrees: “Be the Hero of your Own Story”

Closing Session:
17:15-17:25 Naomi Gefen, Deputy Director General, ALYN Hospital: “The Future of Technology in Rehab”

+
12:10  –  17:25
Hall B

Tango of the Two: Academia and Industry

Co-chairs: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University; Yaron Daniely, PhD, CEO, Yissum

12:10-12:30 Jeroen Tas, Chief Innovation & Strategy Officer, Philips

12:30-12:45 Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem: “Sensor-driven Leap in Drug Development on a Chip” 

12:45-13:00 Arnaldo Mayer, PhD, VP, R&D, Voxellence“Voxellence: AI-powered Radiology”

13:00-13:15 Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University: “Monitoring Sleep Stages at Home”

13:15-13:45 Panel discussion: Lessons Learnt by Researchers
Moderator: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University
Panelists
Prof. David Mirelman, PhD, Weizmann Institute of Science
Prof. Gal Markel, MD, PhD, Tel Aviv University
Prof. Daniel Offen, PhD, Tel Aviv University
Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem

13:45-14:00 Eran Stark, MD, PhD, Sackler Faculty of MedicineTel Aviv University: “Penetrating Neural Probes”

14:00-14:15 Giora Davidovits, President and CEO, Savicell“A Revolutionary Liquid Biopsy, Immunometabolism Platform for High Accuracy, Early Stage Diagnosis of Diseases”

14:10-15:40 Lunch Break

15:40-15:55 Prof. Tal Dvir, PhD, Tel Aviv University: “Printed Heart”

15:55-16:10 Tomer Behor, CEO, RenewSenses“RenewSenses – Conveying Vision Through Sound”

16:10-16:25 Chen Levin, CEO, Xact Robotics Ltd“XACT Robotics – XACTly on Target Every Time”

16:25-16:40 Uzi Sofer, Alpha TAU Medical“First Alpha-radiation Cancer Treatment for Solid Tumors”

16:40-16:55 Tamar Ben-Yedidia, PhD, CSO, BiondVax Pharmaceuticals Ltd: “Update of the Pivotal, Clinical Efficacy, Phase 3 trial of BiondVax’s M-001 Universal Influenza Vaccine”

16:55-17:45 Panel Discussion: It Takes a Village: Boosting the Volume and Quality of Academic Entrepreneurship
Moderator: Yaron Daniely, PhD, CEO, Yissum
Panelists:
Aviv Zeevi, PhD, VP, Technology Infrastructure Division, Israel Innovation Authority
Kelly Krajnik, Senior Manager, Devices, Diagnostics, Mayo Clinic Ventures
Regine Shevach, Managing Director at Inter-Lab, an affiliate of Merck KGaA
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon
Shai Policker, CEO, Medex Xelerator LP

+
12:10  –  17:40
Hall C

New Modalities of Cell Therapies: Revolutionizing the Way We Treat Diseases

Co-chairs: Aya Jakobovits, PhD, Founder, Director, Adicet Bio; Erez Chimovits, Senior Managing Director, OrbiMed Advisors

12:10-12:15 Opening remarks by Co-chairs

12:15-12:40 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Adoptive Cell Therapy 3.0”

12:40-13:05 Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors: “The Cell Therapy Field has already Generated some of the Best Returns in Biotechnology, and the Best is Yet to Come, Based on Enhanced Cell Therapy Technologies”

13:05-13:20 Prof. Angel Porgador, PhD, Ben-Gurion University: “Natural Killer (NK) Cells in Cancer Immunotherapy”

13:20-13:35 Michal J. Besser, PhD, Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology & Director, Wohl GMP Facility, Sheba Medical Center; Assistant Professor, Dept. of Microbiology and Immunology, School of Medicine, Tel Aviv University: “Clinical Experience with In-house Produced CAR T Cells”

13:35-13:50 Stewart Abbot, PhD, Chief Operating Officer, Adicetbio: “Off-the-shelf, Engineered Gamma Delta T-cell Therapies”

13:50-14:05 Merav Beiman, PhD, CEO, ImmPACT-Bio“Next Generation CAR-T Engineering Solving the ‘On-Target’ ‘Off-Tumor’ Issue towards Broader, Safer and Effective CAR-T Therapies”

14:05-14:10 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Session #1 Summary”

14:10-15:40 Lunch Break

15:40-15:55 Yoav Ben Ya’acov, CEO, CTG Pharma: “CTG Pharma- Safe CAR T Therapy for Solid Tumors”

15:55-16:10 Amy W. Schulman, Executive Chair, SQZ Therapeutics“SQZ Biotech: Unleashing the Power of Cells”

16:10-16:25 Julian Adams, PhD, Chief Executive Officer, Gamida Cell“Ex- vivo Expansion of Natural Killer (NK) Cells to Treat B-Cell Lymphoma and Multiple Myeloma”

16:25-16:40 Shmulik Hess, CEO, Enlivex Therapeutics R&D LTD“Enilvex Therapeutics, Immune Rebalancing”

16:40-17:40 Panel Discussion: “The Path for Effective and Accessible Cancer Cell Therapy”
Panelists:
Amy W. Schulman, Executive Chair, SQZ Therapeutics
Aya Jakobovits, PhD, Founder, Director, Adicet Bio
Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors
Stewart Abbot, PhD, Chief Operating Officer, Adicet
Julian Adams, PhD, Chief Executive Officer, Gamida Cell

 

16 May 2019

+
09:30  –  10:50
Hall A

Plenary Session

09:30-10:10 Tom Sudow, Director, Business Development, Cleveland Clinic Innovations; Mark D. Stovsky, MD, MBA, FACS, Senior Director, Emerging Business, Cleveland Clinic Ventures: “The Revolutionary Changes in Healthcare Delivery: From Prevention to Rehabilitation and Everything in Between”

10:10-10:50 Jeroen Tas, Chief Innovation & Strategy Officer, Philips: “Creating the Future of Healthcare Through Digital Innovation”

+
10:50  –  11:20

Coffee Break

+
11:20  –  17:30
Hall A

Transformative Cancer Therapies

Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine; Co-Founder and General Partner, Israel Biotech Fund

11:20-11:25 Opening by Chair

11:25-11:50 Gary Gordon, MD, PhD, Former Vice President, Global Oncology Development, AbbVie, Inc: “The 20 Year Journey of an Oncology Drug”

11:50-12:05 Prof. Elizabeth Croydon, Senior Clinical Director, Oncology – EU Clinical Development, Merck Sharp & Dohme: “MSD Immune-oncology Innovative Therapies”

12:05-12:20 Ruth Ben Yakar, PhD, Chief Executive Officer, BioSight“Biosight Ltd. is Developing BST-236, a Novel Antimetabolite for First-line Treatment of Hematological Malignancies and Disorders”

12:20-12:35 Julian Adams, PhD, Chief Executive Officer, Gamida Cell“Ex Vivo Expanded Cells to Treat Hematological Malignancies”

12:35-12:50 Baruch Schori, Chief Executive Officer, PTM Biosciences“PTM Biosciences is Promoting Precision Medicine by Transforming Post-Translational Modifications into Novel Therapeutic Targets and Biomarkers for Disease Management”

12:50-13:05 Tehila Ben Moshe, PhD, Chief Executive Officer & Co-Founder, Biond Biologics“Biond Biologics: From Innovative Science to the Clinic; Transforming the Treatment of Cancer”

13:05-13:20 Israel Isaac, Chief Executive Officer, Kitov Pharma“NT-219, a First-in-class Dual Inhibitor of STAT3 and IRS1/2 is Overcoming Drug Resistance”

13:20-14:50 Lunch Break

14:50-15:10 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Bi-Specific Antibodies and Fusion Proteins in Cancer Therapy”

15:10-15:25 Prof. Dror Harats, CEO, Vascular Biogenics“Turning ‘Cold’ Tumor into ‘Hot’ Tumor – Lessons from  VB-111, a Viral Immuno-oncology Agent and VB-611, a Novel Bi-specific Antibody”

15:25-15:40 Roni Mamluk, PhD, Chief Executive Officer, Ayala Pharmaceuticals“Ayala Pharmaceuticals – Precision Oncology Targeted Therapy”

15:40-15:55 Frank Haluska, MD, PhD, Chief Executive Ofiicer, Anchiano Therapeutics“Gene Therapy for Early Stage Bladder Cancer: The Pivotal Program with Inodiftagene”

15:55-16:10 Mark Schoenberg, MD, Chief Medical Officer, UroGen Pharma“UroGen Pharma: Paradigm Changing Technology for Urologic Oncology”

16:10-16:25 Asher Nathan, CEO, NeoTX Therapeutics Ltd“Selective T Cell Redirection (STR): A Second Generation Immunotherapy”

16:25-16:40 Amnon Peled, PhD, Chief Executive Officer, Biokine Therapeutics“Development of First in Class High Affinity Small Molecule Antagonist of a Novel Cancer Target Critical for Tumor Cell Migration and Survival”

16:40-17:00 Concluding Remarks

+
11:20  –  17:05
Hall B

Personalized Medicine and Digital Health: Lessons Learned and Challenges Ahead

Co-chairs: Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund; Prof. Varda Shalev, MD, MPA, Managing Director, Kahn-Sagol- Maccab Research and Innovation Institute at Maccabi Health Care Services

11:20-11:40 Fireside Chat – The Future Doctor, Patient and In-between
Prof. Varda Shalev, MD, MPA
, Managing Director, Kahn-Sagol- Maccabi Research and Innovation Institute at Maccabi Health Care Services
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund

11:40-11:55 Oren Oz, CEO, Nuvo Group“Reinventing Pregnancy Monitoring and Management for the 21st Century”

11:55-12:10 Seth Salpeter, CTO, Curesponse“A Next Generation Platform for Definitive Treatment Answers in Personalized Cancer Medicine”

12:10-12:30 Michal Rozen-Zvi, Director, Healthcare Informatics, IBM Research: “Learn from Screening Data and Assessing Breast Cancer Risk”

12:30-12:45 Daniella Gilboa, Chief Scientific Officer and Co-Founder, AIVF“Transforming IVF with the Power of Artificial Intelligence”

12:45-13:05 Uma Makhija, Business Development Lead, Digital Health, Otsuka Pharmaceuticals: “Pharma and Digital Therapeutics Partnerships – Opportunities and Challenges”

13:05-13:20 Lihi Segal, CEO, DayTwo“Personalized Nutrition Recommendations for Normalizing Blood Glucose Levels Based on Microbiome, Medical and Personal Records”

13:20-14:50 Lunch Break

14:50-15:10 Prof. Eitan Friedman, MD, PhD, Director & Founder of The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center

15:10-15:25 Alex Melamud, CEO, Melcap Systems“First Digital Health Affordable System for the Treatment of Overweight and Obesity for Billions”

15:25-15:40 Vince Gao, PhD, Founder & CEO, Govita Tech“Association of Genetic and Metabolic Data Derived from Metabolic Pathways for Personalized Intervention of Chronic Diseases”

15:40-15:55 Erez Gavish, Co-Founder/CEO, 2breathe Technologies Ltd“Can Digital Therapeutics Lower Sympathetic Overactivity?”

15:55-16:15 Elliot Menschik, MD, PhD, Global Head, Healthcare + Life Science Startups, Amazon Web Services: “Re:Inventing Healthcare – Glimpses of Digitally-enhanced, Data-driven Future”

16:15-16:30 Simona Di-Capua, Sr Dir GXR&D Tech & Process Design KFS, Teva“3D Printing – A Novel Approach to Design and Manufacture Personalized Medicines”

16:30-16:45 Lior Wolff, Head of eHealth and Digital Wing at Clalit Health Services“Clalit Health Services Expanding its Telemedicine Offering with TytoCare’s Physical Exam from Home”

16:45-17:05 Wade Ackerman, Partner, FDA Regulatory group, Co-Lead of Digital Health Initiative, Covington & Burling LLP: “Navigating the Evolving Regulation of Personalized Medicine and Digital Health”

+
11:20  –  17:20
Hall C

Cannabis’ Therapeutic Promise: Hope or Hype?

Co-chairs: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem; Ayelet Torem, Adv, Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co

11:20-11:45 Dorman Followwill, Senior Partner, Frost & Sullivan: “Outlook for Cannabis as Therapeutic Agent”

11:45-12:05 Prof. Hinanit Koltai, PhD, Agricultural Research Organization (ARO), Volcani Center: “Medical Cannabis: from Weed to Molecules to Drug Development”

12:05-12:25 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Improvement of CBD and THC Oral Bioavailability using Nano Delivery Systems”

12:25-12:45 Yossi Tam, The Hebrew University of Jerusalem: “Cannabinoid-Based Therapies: Lessons Learned from the Endocannabinoid System”

12:45-13:10 Prof. Raphael Mechoulam, PhD, Hebrew University of Jerusalem: “Cannabinoids: A Look Back and Ahead”

13:20:-14:50 Lunch Break

14:50-15:10 Medy Wiener, MD, Chief Medical Officer, BOL Pharma: “Drug/Cannabinoid Clinical Development Route – Same but Different”

15:10-15:25 Prof. Oded Shoseyov PhD, Co-founder and CSO, GemmaCert Ltd“Remote Sensing of Cannabis; The First Steptowards Standardization and Closing the Learning Cycle”

15:25-15:40 Tamir Gedo, CEO, BOL Pharma“The Winners and Losers of the Global Cannabis Industry”

15:40-15:55 Ascher Shmulewitz, CEO, Therapix Biosciences Ltd“Therapix Biosciences Developing Cannabinoids of the Future”

15:55-16:10 Perry Davidson, CEO, Syqe Medical Ltd: “Medical Cannabis – The Green Elephants in the Room”

16:10-16:25 Dadi Segal, CEO, Panaxia Pharmaceutical Industries Ltd“Panaxia – Manufacturing of Pharmaceutical Cannabis Products”

16:25-16:40 Taher Nassar, VP, Research, Bionanosim Ltd“Bionanosim Ltd-Innovative Nano-Carriers for Improved Cannabis-BNS”

16:40-17:00 Prof. Itamar Raz, MD, Head, The Israeli National Diabetes Council: “Medical Cannabis treatment of Pain and Glycemic Control”

17:00-17:20 Ayelet Torem, Adv., Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co: “Medical Cannabis Regulatory Overview”

 

SOURCE

http://kenes-exhibitions.com/biomed/program/?utm_source=All+Kenes+subscribers+%28divided+by+groups%29&utm_campaign=9ad5bcc465-MIXIII_BIOMED_201_GRAND_OPENING_INVITATION&utm_medium=email&utm_term=0_f956e1b94c-9ad5bcc465-227226585&ct=t(MIXIII_BIOMED_2019_GRAND_OPENING_INVITATION)&goal=0_f956e1b94c-9ad5bcc465-227226585&mc_cid=9ad5bcc465&mc_eid=0311bd1e30

Read Full Post »

Older Posts »